Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
VAL-083
DRUG
2 trials
Sponsors
Kintara Therapeutics, Inc.
, Global Coalition for Adaptive Research
Conditions
Cancer
Glioblastoma
Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Recruiting
NCT03970447
Global Coalition for Adaptive Research
Glioblastoma
Start: 2019-07-30
End: 2030-06-01
Target: 2250
Updated: 2026-04-03
Unknown Phase
Expanded Access to VAL-083
NCT03138629
Kintara Therapeutics, Inc.
Cancer
Updated: 2023-11-22
Related Papers
TIP-10. Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
Neuro-Oncology
2025-11-01
Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.
Journal of Clinical Oncology
2025-05-28
1 citations
LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology
2024-11-01
2 citations
CTNI-72. VAL-083 IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED UNDER EXPANDED ACCESS PROGRAM
Neuro-Oncology
2024-11-01
CTNI-71. RELA FUSION-POSITIVE EPENDYMOMA, DIFFUSE MIDLINE GLIOMA AND GRADE 4 IDH MUTANT ASTROCYTOMA TREATED WITH VAL-083 UNDER EXPANDED ACCESS: CASE REPORTS
Neuro-Oncology
2024-11-01
CTNI-39. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology
2024-11-01
OS09.7.A GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB
Neuro-Oncology
2024-10-01
2 citations
KS03.5.A EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology
2024-10-01
P27.11.A GLOBAL EXPANSION OF GBM AGILE: A PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology
2024-10-01
Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.
Journal of Clinical Oncology
2024-06-01
1 citations
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors
Communications Medicine
2024-05-21
6 citations
CTNI-85. GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB
Neuro-Oncology
2023-11-01
17 citations
P11.29.B UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology
2023-09-01
Immune profiling in patients with glioblastoma treated with VT1021 in a phase I/II expansion study.
Journal of Clinical Oncology
2023-06-01
3 citations
Abstract LB126: RELA fusion-positive ependymoma and diffuse midline glioma treated with VAL-083 under expanded access - case reports
Cancer Research
2023-04-14
1 citations
Abstract LB127: VAL-083 in patients with recurrent glioblastoma treated under expanded access program
Cancer Research
2023-04-14
Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system
Neuro-Oncology Advances
2023-01-01
17 citations
CTNI-27. MULTI-CENTER, PHASE 2 STUDY EVALUATING THE PHARMACOKINETICS, SAFETY AND PRELIMINARY EFFICACY OF PAXALISIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH UNMETHYLATED GLIOBLASTOMA (GBM)
Neuro-Oncology
2022-11-01
1 citations
CTNI-38. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Neuro-Oncology
2022-11-01
DDDR-34. RECURRENT RELA FUSION-POSITIVE EPENDYMOMA TREATED WITH VAL-083 UNDER EXPANDED ACCESS: A CASE REPORT
Neuro-Oncology
2022-11-01
8 more papers not shown